bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Buy" from Brokerages

Retrieved on: 2021-02-12 10:07:11

Tags for this article:

Click the tags to see associated articles and topics

bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Buy" from Brokerages. View article details on hiswai:

Excerpt

Renaissance Technologies LLC now owns 603,700 shares of the biotechnology company's stock valued at $26,122,000 after acquiring an additional ...

Article found on: www.marketbeat.com